
ET World MSME Day: How IDBI Bank is transforming MSME financing
Seeing this,
IDBI Bank
has emerged as a strategic facilitator of MSME development. With a digital-led lending strategy, decentralised credit support, and firm alignment with government-sponsored schemes such as Mudra and PM Vishwakarma, the bank is transforming the way MSMEs surmount legacy hurdles to capital.
"If India has to be a developed economy by 2047, MSMEs will remain at the centre of this journey," said Sumit Phakka, Deputy Managing Director,
IDBI Bank
. Phakka participated in the virtual fireside chat, 'Empowering Indian Enterprises: IDBI Bank's Strategic Blueprint for MSME Growth', on the occasion of ET World MSME Day on June 27, 2025.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Villas For Sale in Dubai Might Surprise You
Villas In Dubai | Search Ads
Get Rates
Undo
IDBI Bank's Roadmap to Strengthen MSMEs | Insights from Sumit Phakka
Sumit Phakka, Deputy Managing Director, IDBI Bank, joined us for an exclusive fireside chat on the topic 'Empowering Indian MSMEs: IDBI Bank's Strategic Blueprint.' He emphasized that the contribution of MSMEs is crucial to India's economic growth, especially in the country's pursuit of becoming a five trillion-dollar economy and achieving developed nation status by 2047. Highlighting the bank's forward-looking approach, he shared that IDBI Bank is actively working to expand its range of digital solutions, ensuring that MSMEs have easy, efficient, and tech-enabled access to financial services tailored to their evolving needs.
Conquering the credit challenge through innovation
Affordable, timely access to credit is the biggest stumbling block for MSMEs. Conventional banking requires collateral, healthy balance sheets, or long credit profiles, which are requirements many small enterprises cannot fulfill.
"New-age MSMEs are not always able to provide collaterals or balance sheets that banks demand. That constrains their competitiveness and prevents them from scaling," Phakka clarified.
Live Events
To fill this gap, IDBI Bank introduced i-MSME Express, a digital underwriting system that uses GST data to evaluate borrower profiles. Whether a new-to-bank or a new-to-credit customer, lending happens fast and in a transparent manner on the basis of real-time, verified data. More than 500 MSMEs have benefited from the i-MSME Express over the last few months, with over Rs 150 crore released in loans of between Rs 10 to Rs 25 lakhs. IDBI is contemplating taking this offering up to Rs 2 crore soon, covering even small and medium businesses.
Supporting MSMEs in distress with SAJAG
Lending growth is not just about the number of sanctioned loans; it's about viable lending. IDBI Bank realises that even the finest MSMEs may experience temporary adversities. For such instances, the bank has created SAJAG, an asset monitoring system based on predictive analytics and early warning indicators to identify stress in MSME accounts ahead of time. As soon as they are reported, corrective measure plans that range from repayment restructuring to bridge lending or even temporary relief are triggered.
'For smaller accounts under Rs 10 lakhs, decisions are made at the branch level itself. Larger cases go through dedicated MSME rehabilitation committees,' Phakka shared. 'Instead of recalling advances, we prefer rehabilitation to help businesses recover.'
Extending beyond lending to strengthening entrepreneurial ecosystems
IDBI Bank's
MSME approach extends to supply chain finance, hand-holding entrepreneurs, and creating deep local roots.
Special asset officers in MSME branches assist entrepreneurs in managing their banking and business growth trajectory. The bank is also working closely with state and district-level officials to spot and nurture emerging business clusters.
'Understanding their entire value chain, from buyers to suppliers, helps us offer better collection and payment solutions,' Sumit Phakka added.
Mudra success and low NPA strategy
IDBI Bank has made a mark with exceptional performance in the Mudra scheme, achieving 101% of its target last year with a low non-performing asset (NPA) ratio in single digits, a rare feat in the micro-lending space. This success is fuelled by data-driven credit decision-making, focused outreach to micro current account holders, and fast turnaround lending through digital channels for borrowers with good GST data, but no formal credit history.
Future-ready growth
For the fiscal year ahead,
IDBI Bank
is targeting a 25% growth in its MSME loan book, building on a 23% increase in the previous year — significantly higher than the industry average. Key strategic goals include:
Doubling the number of MSME-specific branches to 200 from 100
Increasing Credit Support Cells (CSCs) to expedite processing and shorten turnaround time
Scaling digital lending to achieve a Rs 500 crore book in 12-18 months
Improved concentration on clusters of industries to offer customised financial products
Greater involvement in government schemes for nano and micro entrepreneurs.
From technological innovation to grassroots inclusion, IDBI Bank is not only propelling MSME growth, but driving a national shift, one business at a time. As Phakka concluded on ET World MSME Day:
'We pride ourselves in being a true friend to Indian MSMEs. When businesses know their bank stands by them, in growth and in struggle, they are empowered to aim higher.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
8 minutes ago
- Economic Times
RIL announces AGM date, sets August 14 as record date for dividend
Mukesh Ambani-led Reliance Industries (RIL) will hold its 48th Annual General Meeting (AGM) on August 29 at 2 pm. The company has also set August 14 as the record date to determine eligibility of investors for the final dividend for FY25. ADVERTISEMENT On April 25, the company's board had recommended a dividend of Rs 5.50 per equity share for FY25. It was announced along with company's March quarter earnings. The company will pay the dividend within a week of the AGM, RIL said in its filing to the exchanges. The announcement was made after market hours on Thursday and RIL shares today ended at Rs 1,390 on the NSE, declining 1.4%. Reliance shares have rallied 14% on the year-to-date basis. RIL reported a 78% year-on-year increase in its Q1FY26 consolidated net profit to Rs 26,994 crore, compared to Rs 15,138 crore in the year-ago period. The sharp increase in profit was primarily driven by a one-time gain from the sale of the company's stake in Asian Paints, which contributed to Rs 8,924 crore in other income. The profit, attributable to the owners of the company, exceeded Street estimates of Rs 22,069 crore. The company's revenue from operations rose 5.3% to Rs 2,48,660 crore versus Rs 2,36,217 crore in the year ago period. ADVERTISEMENT RIL's earnings before interest, taxes, depreciation and amortization (EBITDA) stood at Rs 58,024 crore in the quarter under review, rising by 36% over Rs 42,748 crore in the corresponding quarter of the last financial the EBITDA margin for the quarter ended June 30, 2025, stood at 21.2%, rising 460 bps over 16.6% in Q1FY25. ADVERTISEMENT RIL's gross revenue increased by 6% YoY to Rs 2,73,252 crore ($ 31.9 billion). The Jio Platform revenue increased by 18.8% YoY due to strong subscriber growth across mobility and homes, increased consumption and sustained positive momentum in digital services. (You can now subscribe to our ETMarkets WhatsApp channel)
&w=3840&q=100)

Business Standard
11 minutes ago
- Business Standard
Eicher Motors Q1 net rises 9% to Rs 1,205 cr on record Royal Enfield sales
Eicher Motors reported a 9.4 per cent rise in consolidated net profit to Rs 1,205 crore for the first quarter of FY2025–26, compared to Rs 1,101 crore in the same period last year. The growth was driven by record revenue and robust vehicle sales by both Royal Enfield and VE Commercial Vehicles (VECV). The company posted its best-ever Q1 revenue from operations at Rs 5,042 crore, up 14.8 per cent from Rs 4,393 crore in the year-ago quarter. EBITDA stood at Rs 1,203 crore, up 3.2 per cent from Rs 1,165 crore. Royal Enfield sold 261,326 motorcycles during the quarter, a 14.7 per cent year-on-year increase from 227,736 units in Q1 FY2024–25. Managing Director of Eicher Motors and CEO of Royal Enfield, B Govindarajan, said the brand sustained its growth momentum through product innovation and a continued focus on immersive riding experiences. 'The refreshed Hunter 350 continues to be a key marker of growth for us, both in terms of volumes and community engagement,' Govindarajan noted. He also highlighted the expansion in the SAARC region and the launch of the locally assembled Classic 350 in Nepal as part of the company's global ambition. VE Commercial Vehicles (VECV), a joint venture of Eicher Motors, posted revenue of Rs 5,671 crore in Q1 FY26, a rise of 11.9 per cent from Rs 5,070 crore a year ago. EBITDA surged 32.6 per cent to Rs 511 crore from Rs 385 crore. VECV sold 21,610 vehicles in the quarter, up 9.7 per cent year-on-year from 19,702 units. Vinod Aggarwal, managing director and CEO of VECV and vice-chairman of Eicher Motors, said VECV delivered its best-ever Q1 performance. Market share rose to 18.7 per cent from 17.3 per cent a year earlier, driven by 34.5 per cent share in light and medium-duty (LMD) trucks and a strong 14.8 per cent volume growth in buses. The bus segment's market share rose to 21.5 per cent. While VECV's revenue and EBITDA are not included in Eicher Motors' consolidated figures, the company's share of profits from the joint venture is accounted for as a single line item in the consolidated profit after tax. The strong performance of both Royal Enfield and VECV reinforces Eicher Motors' continued growth trajectory across its core segments.
&w=3840&q=100)

Business Standard
11 minutes ago
- Business Standard
Mankind Pharma Q1 PAT drops 17.4% despite 24% revenue growth, costs surge
Delhi-based pharmaceutical major Mankind Pharma reported a 17.4 per cent year-on-year (YoY) decline in consolidated profit after tax (PAT) for the first quarter of FY2025–26 (Q1 FY26), at Rs 445 crore, down from Rs 538 crore in the same quarter last year. The company attributed the fall in profitability to a rise in raw material costs, higher component consumption, and increased employee expenses. Despite the PAT decline, revenue from operations grew significantly—by 24 per cent YoY—to Rs 3,570 crore from Rs 2,867 crore in Q1 FY25. At the operating level, earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to Rs 850 crore in the quarter under review, compared to Rs 675 crore a year ago. The adjusted EBITDA margin improved slightly to 23.8 per cent from 23.6 per cent in the corresponding period last year. Rajeev Juneja, vice chairman and managing director of Mankind Pharma, said the growth in revenue and margins was driven by strong performance in the chronic and consumer healthcare segments, and by the consolidation of Bharat Serums and Vaccines (BSV), acquired in October 2024 for Rs 13,768 crore. A key drag on the bottom line was finance costs, which rose sharply to Rs 170.65 crore in Q1FY26—17 times higher than Rs 10.84 crore in Q1FY25—largely due to financing related to the BSV acquisition. Mankind Pharma said its chronic therapies business outperformed the Indian Pharma Market (IPM) by 1.4x, with cardiac and antidiabetics segments growing 1.5x and 1.6x faster, respectively. Domestic business revenue rose 18.9 per cent YoY to Rs 3,101 crore. The consumer healthcare segment posted a 15 per cent increase in revenue, led by consistent secondary sales growth for key brands such as Manforce condoms and Gas-O-Fast. The company's exports segment recorded a strong 81 per cent YoY growth, supported by a ramp-up in base business and integration of BSV's global operations. Mankind Pharma announced its results post-market hours. Its stock closed marginally lower by 0.28 per cent at Rs 2,567.75 per share on the Bombay Stock Exchange (BSE) on Thursday. The company remains optimistic about sustaining momentum in both chronic therapies and consumer brands, while continuing to integrate BSV's operations for long-term value creation.